The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC)

Journal of Medical Genetics

Volumn 42, Issue 10, 2005, Pages 769-773

  Kruger S ^a   Bier, A ^a   Engel, C ^b   Mangold, E ^c   Pagenstecher, C ^c   Von Knebel Doeberitz, M ^d   Holinski Feder, E ^e   Moeslein, G ^f   Schulmann, K ^g   Plaschke, J ^a   Ruschoff J ^h   Schackert, H K ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h KLINIKUM KASSEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CODON; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS;

EID: 26944440071     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.028506     Document Type: Article

References (41)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
2. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78.
3. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995;81:1013-20.
4. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
5. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
6. Storey A, Thomas M, Kalita A, Norwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Mattashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
7. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998;352:871-2.
8. Lanham S, Campbell I, Watt P, Gornall R. p53 polymorphism and risk of cervical cancer. Lancet 1998;352:1631.
9. Hayes VM, Hofstra RM, Buys CH, Hollema H, van der Zee AG. Homozygous arginine 72 in wild type p53 and risk of cervical cancer. Lancet 1998;352:1756.
10. Heiland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature 1998;396:530-1.
11. Josefsson AM, Magnusson PK, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO, Gyllensten UB. p53 polymorphism and risk of cervical cancer. Nature 1998;396:531.
12. Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF Jr, Herrero R, Bratti MC, Schwartz P, Mortel R, Barnes W, Greenberg M, McGowan L, Scott DR, Martin M, Herrera JE, Carrington M. p53 polymorphism and risk of cervical cancer. Nature 1998;396:531-2.
13. Klaes R, Ridder R, Schaefer U, Benner A, von Knebel Doeberitz M. No evidence of p53 allele-specific predisposition in human papillomavirus- associated cervical cancer. J Mol Med 1999;77:299-302.
14. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999;354:218-19.
15. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L. p53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995;16:2233-6.
16. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckman G. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16:1461-4.
17. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. he codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
18. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996;2:169-74.
19. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri PJ, Boland CR. Genetics, natural history, tumour spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993;104:1535-49.
20. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Monr J, Fodde R, Khan PM. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7.
21. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-61.
22. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
23. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074-80.
24. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin Dl polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-52.
25. Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I, Luthra R, Lynch PM, Amos CI. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 2001;61:1269-71.
26. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
27. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 1999;5:937-41.
28. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001;61:1508-16.
29. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-84.
30. Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R. Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet 1997;17:114-18.
31. Toft NJ, Curtis LJ, Sansom OJ, Leitch AL, Wyllie AH, te Riele H, Arends MJ, Clarke AR. Heterozygosity for p53 promotes microsatellite instability and tumourigenesis on a Msh2 deficient background. Oncogene 2002;21:6299-306.
32. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
33. Kruger S, Plaschke J, Pistorius S, Jeske B, Haas S, Kramer H, Hinterseher I, Bier A, Kreuz FR, Theissig F, Saeger HD, Schackert HK. Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis colorectal cancer. Hum Mutat 2002;19:82.
34. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, Gerwin BI, Harris CC. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991;51:4090-6.
35. Mariashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
36. Farrington SM, McKinley AJ, Carothers AD, Cunningham C, Bubb VJ, Sharp L, Wyllie AH, Dunlop MG. Evidence for an age-relatea influence of microsatellite instability on colorectal cancer survival. Int J Cancer 2002;98:844-50.
37. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-9.
38. Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP, Clarke AR. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci USA 1999;96:3911-15.
39. Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeau F, Girodet J, Salmon RJ, Thomas G. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 1997;94:12122-7.
40. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-15.
41. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992;89:9210-14.